Skip to main content

Table 2 VHL mutations and HLA types in vaccinated patients

From: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Pt DNA mutation Protein mutation HLA-A HLA-B HLA-DR HLA-DQ
1 del TT 443-444 148 Phe-Cys fsX25 02 15, 40 04, 13 03, 06
2 T-C 497 166 Val-Ala 02,11 3701, 4001 1001, 13 0501, 06
3 G-T 332 111 Ser-Ile 03, 29 14, 35 01, 13 05, 06
4 C-G 343 115 His-Asp 02 07, 40 1302, 1501 ND
5 del C 183 62 Val-Cys fsX5 03,29 35, 44 01, 13 0501, 06
6 ins C 346-347 116 Leu-Pro fsX16 02,31 40, 51 0404, 11 0301, 0302
  1. Abbreviations: del = deletion; fs = frameshift; X = stop codon; ins = insertion.
  2. Patient 1 had a deletion of a thymine at two nucleotides (443 and 444) that resulted in a predicted frameshift starting at codon 148 with a phenylalanine to cysteine amino acid change, extending for 23 more codons, and ending with a premature stop codon at position 172. Patient 2 had a mutation at nucleotide number 497 resulting in a change from thymine to cytosine which led to a substitution in valine to alanine at position 166. Patient 3 had a mutation at nucleotide number 332 resulting in a change from guanine to thymine that led to a substitution in serine to isoleucine at position 111. Patient 4 had a mutation at nucleotide number 343 resulting in a change from cytosine to guanine which led to a substitution from histidine to aspartic acid at position 115. Patient 5 had a deletion of a cytosine at nucleotide number 183 that resulted in a predicted frameshift starting at codon 62 with a valine to cysteine amino acid change, extending for 3 more codons, and ending with a premature stop codon at position 66. Patient 6 had an insertion of a cytosine between two nucleotides (346 and 347) that resulted in a predicted frameshift starting at codon 116 with a leucine to proline amino acid change, extending for 14 more codons, and ending with a premature stop codon at position 131.